# EVER: New drug application for TRABECTEDIN

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | EVER |
| Product | TRABECTEDIN |
| Generic / ingredient | TRABECTEDIN |
| Approval | New drug application (NDA) |
| Application | NDA219617 |
| Decided | 2026-10-01 |
| Panel / class | POWDER, INTRAVENOUS |

## Why this score
- A new product launch.

Source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration) (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219617). Last refreshed: 2026-11-04T06:06:18.796Z.
From openFDA (PMA and Drugs@FDA). openFDA can lag FDA decisions by days to weeks. Drug supplement types follow the FDA submission class (labeling and REMS, manufacturing/CMC, efficacy, other). Company and product level only. Verify on FDA databases before relying on an approval.